[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367277-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367277-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","urinary-microbiota-changes-among-nmibc-patients-during-bcg-therapy-comparing-bcg-responders-and-non-responders","Urinary microbiota changes among NMIBC patients during BCG therapy - comparing BCG responders and non-responders","","Gold-standard management of high-risk non-muscle-invasive bladder cancer combines transurethral resection of tumor tissue with BCG immunotherapy, yet a reliable biomarker predicting BCG efficacy and response remains unavailable. Urinary microbiota is suggested to influence treatment outcomes. This original research examined changes in urinary microbiota across six induction BCG cycles and assessed whether baseline and treatment-associated microbiome features predicted responders versus non-responders using 16S rRNA sequencing of catheterized urine.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/urinary-microbiota-changes-among-nmibc-patients-during-bcg-therapy-comparing-bcg-responders-and-non-responders/367277/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/urinary-microbiota-changes-among-nmibc-patients-during-bcg-therapy-comparing-bcg-responders-and-non-responders/367277.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of this study on BCG treatment for NMIBC?","Question",{"text":63,"@type":64},"To assess how urinary microbiota changes during the six induction BCG cycles and to determine whether microbiota patterns can predict BCG treatment outcomes in responders versus non-responders.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were urinary microbiota samples collected and analyzed?",{"text":68,"@type":64},"Catheterized urine samples were collected before each of the six BCG doses, and bacterial composition was analyzed using 16S rRNA gene sequencing.",{"name":70,"@type":61,"acceptedAnswer":71},"What microbiota differences were observed between BCG responders and non-responders?",{"text":72,"@type":64},"Non-responders showed a higher abundance of the genus Aureispira and a markedly lower abundance of the species Negativicoccus succinivorans before starting BCG. During therapy, Aureispira abundance decreased, with a larger reduction by the end among non-responders.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367277,1790211929,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 10 March 2025  \nDOI 10.3389/fcimb.2025.1479795  \nOPEN ACCESS  \nEDITED BY  \nShomik Sengupta,  \nMonash University, Australia  \nREVIEWED BY  \nMogana Rajagopal, UCSI University, Malaysia Matej Medvecky,  \nUniversity of Warwick, United Kingdom  \n*CORRESPONDENCE  \nJanoˇs Terzic´  \n[janos.terzic@mefst.hr](janos.terzic@mefst.hr)  \nRECEIVED 12 August 2024  \nACCEPTED 17 February 2025  \nPUBLISHED 10 March 2025  \nCITATION  \nBoban T, Milic´ Roje B, Knezovic´ D, Jeronˇcic´ A, ˇSoˇsic´ H, ˇSitum M and Terzic´ J (2025) Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCGresponders and non-responders.  \nFront. Cell. Infect. Microbiol. 15:1479795 .  \ndoi: 10.3389/fcimb.2025.1479795  \nCOPYRIGHT  \n© 2025 Boban, Milic´ Roje, Knezovic´, Jeronˇcic´,ˇSoˇsic´, ˇSitum and Terzic´ . This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nUrinary microbiota changes among NMIBC patients during BCG therapy: comparing BCGresponders and non-responders  \nToni Boban 1, Blanka Mili´c Roje 2, Dora Knezovi´c2, Ana Jeronˇci´c3, Hrvoje ˇSoˇsi´c1, Marijan ˇSitum 1 and Janoˇs Terzi´c2*  \n1 Department of Urology, University Hospital of Split, Split, Croatia, 2 Laboratory for Cancer Research, University of Split School of Medicine, Split, Croatia, 3 Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia  \nThe gold standard for treating high-risk non-muscle-invasive bladder cancer involves the transurethral removal of cancerous tissue followed by BCG immunotherapy. So far, there is no reliable biomarker for predicting BCGefﬁcacy and identifying patients who will or will not respond to BCG treatment. Emerging evidence suggests that urinary microbiota may play a crucial role in BCGefﬁcacy. This study aimed to explore (i) changes in urinary microbiota during the six induction cycles of BCG and (ii) its potential predictive role in determining the outcome of BCG treatment. To this end, catheterized urine samples were collected before each of the six BCG doses and bacterial composition was analyzed using 16S rRNA gene sequencing. Patient inclusion criteria were male gender, no previous history of urothelial cancer, no other malignancies, no active infection, and no antibiotic usage for at least 20 days before the ﬁrst BCG dose. We observed a signiﬁcant decrease in biodiversity, measured by the Shannon Index, during the ﬁrst week of therapy in 10 out of 12 patients (p=0 . 021) . Additionally, differences in microbiota composition before the start of BCG therapy were noted between responders and non-responders to BCG therapy. Non-responders exhibited a 12 times higher abundance of genus Aureispira (p\u003C0 . 001), and, at the species level, a 27-fold lower abundance of Negativicoccus succinivorans (p\u003C0 . 001) . Throughout the treatment, the abundance of the genus Aureispira decreased, showing an eightfold reduction by the end of therapy among nonresponders (p\u003C0 . 001) . Our ﬁndings suggest that urinary microbiota plays an active role before and during the course of BCG therapy. However, this is a preliminary study, and further research involving larger patient cohorts is needed.  \nKEYWORDS  \nurinary microbiome, non-muscle invasive bladder cancer, BCG, response to therapy, immunotherapy  \nFrontiers in Cellular and Infection Microbiology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nAccording to the latest GLOBOCAN data, bladder cancer is the 10th most common cancer globally, with an estimated 549,000 new cases and 200,000 deaths yearly. Incidence among men is four time","cbCaigMQXxHUhw3A","https://ap.wps.com/l/cbCaigMQXxHUhw3A","pdf",4725856,11,"English","# Introduction\n# Methods\n# Results\n## Biodiversity changes during induction therapy\n## Microbiota composition differences by response\n# Discussion\n# Conclusions","[{\"question\":\"What was the main aim of this study on BCG treatment for NMIBC?\",\"answer\":\"To assess how urinary microbiota changes during the six induction BCG cycles and to determine whether microbiota patterns can predict BCG treatment outcomes in responders versus non-responders.\"},{\"question\":\"How were urinary microbiota samples collected and analyzed?\",\"answer\":\"Catheterized urine samples were collected before each of the six BCG doses, and bacterial composition was analyzed using 16S rRNA gene sequencing.\"},{\"question\":\"What microbiota differences were observed between BCG responders and non-responders?\",\"answer\":\"Non-responders showed a higher abundance of the genus Aureispira and a markedly lower abundance of the species Negativicoccus succinivorans before starting BCG. During therapy, Aureispira abundance decreased, with a larger reduction by the end among non-responders.\"}]","Urinary microbiota changes among NMIBC patients during BCG therapy - comparing BCG responders and non-responders | PDF",1790170050,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0d8dc7fa41703e287be0365fd34c46f.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b3484402480c8dabd6343a2ec14dbdc.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a00e2a0417802e0abfbdb190d6fe3f96.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d9be5a0c1db54d57753a10d8e16337.webp",980,1385]